I was diagnosed with MS two years ago. My doctor never did an AQP4 antibody test. Should I be worried?

Yes—if you have had optic neuritis, a spinal cord attack, or intractable hiccups, you should be assessed for NMO. Approximately 20% of demyelinating disorder patients in India have NMO rather than MS. If you are on natalizumab, fingolimod, or alemtuzumab and your AQP4-IgG was never checked, this is urgent as these medications may be harmful in NMO.

My vision has not come back after my NMO optic neuritis attack. Is it gone permanently?

Late recovery is less common in NMO than MS, but OCT assessment can indicate if residual tissue remains. The priority is preventing the next attack, as each one causes additional damage. Effective relapse prevention is the most important intervention to protect remaining vision.

What is the difference between NMO and MOGAD?

Both cause vision and spinal cord issues, but they involve different antibodies. MOGAD tends to affect men and women equally, occurs in younger patients, and generally has a better prognosis per attack. The newer complement-targeted biologics for AQP4+ NMO are not indicated for MOGAD.

My NMO has been stable for two years on rituximab. Can I stop?

This requires careful specialist discussion. NMO relapses are severe and irreversible. Current evidence does not support routine withdrawal. Any change must be planned in detail with the KIMS team, especially when considering pregnancy.

I had three days of severe hiccups and vomiting. My gastroenterologist found nothing. Could this be NMO?

Yes—intractable hiccups/vomiting (Area Postrema Syndrome) is a recognized NMO brainstem presentation. If you have any history of visual loss or limb weakness, seek neurological assessment at KIMS urgently for an MRI and AQP4-IgG test.

How often do I need rituximab infusions and what monitoring is required?

Usually every 6 months, adjusted based on CD19/CD20 B-cell monitoring. We monitor blood counts, renal/liver function, and hepatitis B status. The infusion is a 4-6 hour day procedure at KIMS.

EMERGENCY:Sudden loss of vision, rapid leg weakness, or loss of bladder control —call040-46324365immediately — 24 hours, 7 days— 24/7

DEMYELINATING & INFLAMMATORY DISORDERS

Neuromyelitis Optica (NMO / NMOSD): Severe Autoimmune Care in Hyderabad

NMO is proportionately more common in India than in the West and is frequently misdiagnosed as MS. Correct diagnosis and AQP4 testing at KIMS Neuroscience are life-critical.

Call 040-44885000

Diagnosis at KIMS

The Condition That Destroys Vision and Causes Paralysis

NMOSD was originally considered a subvariant of multiple sclerosis but is now recognized as a distinct disorder. In India, NMO phenotype disorders constitute nearly 20% of demyelinating disorders—a proportion far higher than in Western populations.

A 34-year-old woman presented to KIMS. She was previously treated for MS but continued to have devastating relapses, including leg paralysis. Her AQP4-IgG test—never performed elsewhere—came back strongly positive. The MS medication she was taking was not only ineffective but may have worsened her condition.

At KIMS Neuroscience, no patient presenting with optic neuritis or transverse myelitis is started on MS-specific therapy until the AQP4-IgG test result is known. This distinction is life-critical because certain MS drugs can trigger catastrophic NMO relapses.

What NMO Is vs MS

In MS, the immune system attacks myelin. In NMO, the target is aquaporin-4 water channels on astrocytes. This causes astrocyte death and tissue destruction far more aggressive than MS. Recovery from an NMO attack is typically incomplete, making relapse prevention the absolute priority.

NMO Specialist Review

Specialized AQP4/MOG testing and relapse prevention protocols.

040-44885000Emergency: 040-46324365

Recognizing NMOSD

Core Clinical Symptoms

NMOSD primarily targets the optic nerves, spinal cord, and brainstem. Understanding these six presentations enhances diagnostic precision.

Optic Neuritis (Vision Loss)

NMO optic neuritis is typically more severe than MS optic neuritis. It may affect both eyes simultaneously or sequentially. The visual loss is often severe—hand-movement vision or worse. Pain on eye movement is common, and recovery is often incomplete without rapid treatment.

Transverse Myelitis (Weakness & Bladder Dysfunction)

Characteristic long segment cord involvement (LETM) spanning 3+ vertebral levels. Produces rapidly progressive limb weakness (often reaching paraplegia within hours), sensory loss, and bladder/bowel dysfunction.

Area Postrema Syndrome (Hiccups & Vomiting)

A highly characteristic and frequently missed symptom. It causes intractable hiccups and vomiting lasting days to weeks, often misdiagnosed as a GI problem rather than a neurological emergency.

Brainstem Syndrome

Produces symptoms like diplopia (double vision), facial numbness, severe vertigo, difficulty swallowing, or dysarthria (slurred speech) depending on the lesion location.

Narcolepsy-like attacks

Hypothalamic lesions in NMO can produce acute-onset excessive daytime sleepiness and sleep-wake disturbances.

Symptomatic Cerebral Syndrome

Brain involvement can produce large, oedematous lesions leading to encephalopathy, confusion, or seizures—distinct from the small lesions seen in MS.

Life-Critical Warning

The MS Misdiagnosis Cost

Misdiagnosing NMO as MS is the most consequential error. MS drugs target different immune pathways and can be actively harmful in NMO.

Harmful MS Medications for NMO:

• Natalizumab: Associated with severe NMO worsening.

• Fingolimod: Associated with NMO relapses.

• Alemtuzumab: Associated with NMO relapses.

• Interferon beta: No proven benefit and potential for harm.

The NMO Spectrum

AQP4-IgG Seropositive

The classic form, affecting water channels. Highly common in Asian populations.

MOG-IgG (MOGAD)

Targets myelin oligodendrocyte glycoprotein. Better prognosis than AQP4+ but requires specific care.

Double-Seronegative

Neither antibody present, but clinical features match. Requires expert MRI assessment.

KIMS Diagnostic Protocol

How We Confirm NMO

1

AQP4-IgG Serology (Serum)

The essential first test. Positive in 70–80% of classic NMO cases. At KIMS, this is performed on all patients with optic neuritis or transverse myelitis before starting MS therapies.

2

MOG-IgG Serology

Performed concurrently to identify MOGAD, which overlaps clinically with NMO but requires a distinct management approach.

3

Spine MRI with Gadolinium

Identifies the hallmark Longitudinally Extensive Transverse Myelitis (LETM) spanning three or more vertebral levels.

4

Brain MRI

Used to exclude MS patterns and identify NMO-specific distributions adjacent to the third ventricle, hypothalamus, and area postrema.

5

Optical Coherence Tomography (OCT)

Measures retinal nerve fibre layer thinning, which is typically more severe and bilateral in NMO than in MS.

6

Lumbar Puncture (CSF Analysis)

NMO CSF often shows inflammatory pleocytosis. Critically, Oligoclonal bands—the MS marker—are typically absent or transient in NMO.

Treatment

Treatment & Relapse Prevention

Because each NMO attack causes permanent damage, our goal is zero relapses.

Emergency Phase

Acute Attack: Steroids & PLEX

High-dose IV Methylprednisolone is started urgently. For steroid-refractory attacks (severe myelitis or vision loss), Plasmapheresis (Plasma Exchange) is used to physically remove AQP4 antibodies from the blood.

Gold Standard

Rituximab Therapy

The mainstay of NMO prevention at KIMS. Given as IV infusions every 6 months. It is the most cost-effective long-term therapy in India for preventing relapses and maintaining disability scores.

Advanced Care

Newer Biologic Therapies

Eculizumab, inebilizumab, satralizumab, and ravulizumab are available for appropriate patients, especially those with breakthrough activity on rituximab or specific seropositive profiles.

NMO in India: Specific Challenges

Younger Onset: In Indian cohorts, the mean age of onset is 26.6 years—much younger than the Western average of 40. This strikes women at their most productive lives.

Rituximab Advantage: Indian biosimilars make this highly effective treatment affordable compared to the prohibitively expensive newer biologics used in the West.

Diagnostic Delay: Area postrema syndrome is often misdiagnosed as GI issues, and optic neuritis as simple eye problems. These delays cause permanent disability.

Pregnancy & NMO

Unlike MS, NMO carries a significant post-partum relapse risk. Pregnancy planning at KIMS involves joint neuro-obstetric consultation to safely manage medication cycles.

Related Conditions

Multiple Sclerosis Transverse Myelitis ADEM Demyelinating Disorders

FAQs

Frequently Asked Questions

NMO attacks fast and leaves permanent damage. The AQP4 blood test takes one day. Not doing it costs years.

At KIMS Neuroscience, every patient with optic neuritis or spinal cord attacks receives AQP4-IgG and MOG-IgG testing before therapy starts. Whether you need acute steroid pulse therapy, plasmapheresis, or long-term rituximab monitoring, our team ensures every attack prevented is a disability prevented.

040-44885000

International enquiries: info@kimsneurosciences.com